BMO Capital Positive on Abbvie (ABBV) Humira Win Versus Amgen (AMGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
AbbVie (ABBV) Taps Session High
January 15, 2016 10:32 AM ESTAbbVie (NYSE: ABBV) advanced to session highs Friday morning, rising 3.3%.
Amgen (AMGN) Rejected in Challenges to Abbvie (ABBV) Patents on Humira - Bloomberg
January 14, 2016 3:58 PM ESTAmgen (NASDAQ: AMGN) Rejected in Challenges to Abbvie (NYSE: ABBV) Patents on Humira - Bloomberg
... MoreUPDATE: AbbVie (ABBV) Pops on Amgen-Related IPR Patent Chatter
January 14, 2016 3:43 PM EST(Updated - January 14, 2016 3:49 PM EST)
AbbVie (NYSE: ABBV) pops to session highs.
UPDATE - AbbVie is said to be gaining on denial of Amgen's (Nasdaq: AMGN) IPR patent reexaminations covering the '157 and '158 patents, according to market chatter.
Shares of AbbVie rose as much as 11 percent on Thursday's session.
... More